Narayan Kailash, van Dyk Sylvia, Bernshaw David, Rajasooriyar Chrishanthi, Kondalsamy-Chennakesavan Srinivas
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1529-35. doi: 10.1016/j.ijrobp.2008.10.085. Epub 2009 May 25.
To compare patterns of failure, late toxicities, and survival in locally advanced cervical cancer patients treated by either low-dose-rate (LDR) or conformal high-dose-rate (HDRc) brachytherapy as a part of curative radiotherapy.
A retrospective comparative study of 217 advanced cervix cancer patients was conducted; 90 of these patients received LDR and 127 received HDRc brachytherapy. All patients were staged using International Federation of Gynecology and Obstetrics (FIGO) rules, had pretreatment magnetic resonance imaging (MRI), and were treated with concurrent cisplatin chemoradiotherapy. Both groups matched for FIGO stage, MRI tumor volume, and uterine invasion status.
Local and pelvic failures were similar 12-13% and 14% both in both groups. Abdominal and systemic failures in LDR group were 21% and 24%, whereas corresponding failures in HDRc group were 20% and 24%. Sixty-eight percent (87/127) of patients treated by HDRc remained asymptomatic, whereas 42% (38/90) of patients were asymptomatic from the bowel and bladder symptoms after treatment with LDR. The 5-year OS rate was 60% (SE = 4%). The 5-year failure-free survival rate was 55% (SE = 3%). There was no significant difference between the groups.
Image-guided HDRc planning led to a large decrease in late radiation effects in patients treated by HDRc. Patterns of failure and survival were similar in patients treated either by LDR or HDRc.
比较低剂量率(LDR)或适形高剂量率(HDRc)近距离放射治疗作为根治性放疗一部分的局部晚期宫颈癌患者的失败模式、晚期毒性反应和生存率。
对217例晚期宫颈癌患者进行回顾性比较研究;其中90例患者接受LDR治疗,127例接受HDRc近距离放射治疗。所有患者均按照国际妇产科联盟(FIGO)规则进行分期,治疗前进行磁共振成像(MRI)检查,并接受顺铂同步放化疗。两组在FIGO分期、MRI肿瘤体积和子宫浸润状态方面相匹配。
两组的局部和盆腔失败率相似,均为12%-13%和14%。LDR组的腹部和全身失败率分别为21%和24%,而HDRc组相应的失败率为20%和24%。接受HDRc治疗的患者中有68%(87/127)无症状,而接受LDR治疗后,42%(38/90)的患者肠道和膀胱症状无症状。5年总生存率为60%(标准误=4%)。5年无失败生存率为55%(标准误=3%)。两组之间无显著差异。
图像引导的HDRc计划使接受HDRc治疗的患者晚期放射效应大幅降低。LDR或HDRc治疗的患者失败模式和生存率相似。